Impact of benralizumab on asthma exacerbation-related medical healthcare resource utilization and medical costs: results from the ZEPHYR 2 study

Yen Chunga BioPharmaceuticals Medical, AstraZeneca, Wilmington, DE, USACorrespondence[email protected]

Diego J. Masellib Division of Pulmonary Diseases & Critical Care Medicine, University of Texas Health, San Antonio, TX, USA

Fan Muc Analysis Group, Inc, Boston, MA, USA

Erin E. Cookc Analysis Group, Inc, Boston, MA, USA

Danni Yangc Analysis Group, Inc, Boston, MA, USA

Joshua A. Youngc Analysis Group, Inc, Boston, MA, USA

Keith A. Bettsd Analysis Group, Inc, Los Angeles, CA, USA

Eduardo Genofrea BioPharmaceuticals Medical, AstraZeneca, Wilmington, DE, USA

Donna Carstensa BioPharmaceuticals Medical, AstraZeneca, Wilmington, DE, USA

Your download is now in progress and you may close this window